PMID- 25082095 OWN - NLM STAT- MEDLINE DCOM- 20150522 LR - 20181202 IS - 1879-0887 (Electronic) IS - 0167-8140 (Linking) VI - 112 IP - 2 DP - 2014 Aug TI - Involved-nodal radiation therapy leads to lower doses to critical organs-at-risk compared to involved-field radiation therapy. PG - 279-83 LID - S0167-8140(14)00286-2 [pii] LID - 10.1016/j.radonc.2014.06.018 [doi] AB - BACKGROUND: Involved field radiotherapy (IFRT) after cytotoxic chemotherapy has become the standard of care in treating pediatric patients with Hodgkin lymphoma. However, recent interest in shrinking the treatment volume to involved node radiotherapy (INRT) may allow lower doses to critical organ structures. We dosimetrically compared IFRT and INRT treatment approaches. METHODS: INRT treatment plans were retrospectively constructed from 17 consecutively treated pediatric patients identified with Hodgkin lymphoma who had been previously treated with conventional IFRT. The radiation doses delivered to organs-at-risk (OARs) with virtual INRT treatment plans based on INRT field design were then compared to the original IFRT treatment plans. Metrics for comparison included mean doses to organs and volumes of organ receiving at least 50% of the original prescription dose (V50%). A one-tailed, paired t-test was then performed to verify statistical significance at an alpha level of 0.05. RESULTS: All organs at risk compared in this investigation (kidneys, heart, thyroid, parotids, and lungs) had significantly lower doses of radiation with INRT when compared to IFRT (p<0.05). Furthermore, the volume of the breast receiving at least 50% of the initial prescription dose was statistically lower in the INRT plans. CONCLUSIONS: Utilizing the concept of INRT results in a reduction of radiation dose to critical organ structures in pediatric patients with Hodgkin lymphoma when compared to the more traditional method of IFRT. CI - Copyright (c) 2014 Elsevier Ireland Ltd. All rights reserved. FAU - Mulvihill, David J AU - Mulvihill DJ AD - Dept of Radiation Oncology, Rutgers Cancer Institute of NJ, New Brunswick, United States. FAU - McMichael, Kevin AU - McMichael K AD - Dept of Radiation Oncology, Rutgers Cancer Institute of NJ, New Brunswick, United States. FAU - Goyal, Sharad AU - Goyal S AD - Dept of Radiation Oncology, Rutgers Cancer Institute of NJ, New Brunswick, United States. FAU - Drachtman, Richard AU - Drachtman R AD - Dept of Pediatric Oncology, Rutgers Cancer Institute of NJ, New Brunswick, United States. FAU - Weiss, Aaron AU - Weiss A AD - Dept of Pediatric Oncology, Rutgers Cancer Institute of NJ, New Brunswick, United States. FAU - Khan, Atif J AU - Khan AJ AD - Dept of Radiation Oncology, Rutgers Cancer Institute of NJ, New Brunswick, United States. Electronic address: khanat@cinj.rutgers.edu. LA - eng PT - Journal Article DEP - 20140728 PL - Ireland TA - Radiother Oncol JT - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology JID - 8407192 SB - IM MH - Antineoplastic Combined Chemotherapy Protocols/therapeutic use MH - Chemoradiotherapy MH - Hodgkin Disease/drug therapy/*radiotherapy MH - Humans MH - Lymph Nodes/*radiation effects MH - Lymphatic Metastasis MH - Organs at Risk/radiation effects MH - Radiotherapy Planning, Computer-Assisted/*methods MH - Retrospective Studies OTO - NOTNLM OT - Hodgkin lymphoma OT - INRT OT - Involved nodal radiation therapy EDAT- 2014/08/02 06:00 MHDA- 2015/05/23 06:00 CRDT- 2014/08/02 06:00 PHST- 2013/12/02 00:00 [received] PHST- 2014/06/25 00:00 [revised] PHST- 2014/06/30 00:00 [accepted] PHST- 2014/08/02 06:00 [entrez] PHST- 2014/08/02 06:00 [pubmed] PHST- 2015/05/23 06:00 [medline] AID - S0167-8140(14)00286-2 [pii] AID - 10.1016/j.radonc.2014.06.018 [doi] PST - ppublish SO - Radiother Oncol. 2014 Aug;112(2):279-83. doi: 10.1016/j.radonc.2014.06.018. Epub 2014 Jul 28.